3 Indian Export Stocks With High US Revenue Exposure

India and the US are circling a trade deal without quite sealing it, and that limbo is exactly where some export heavy Indian stocks live. Policy risk around tariffs can rattle sentiment or quietly set up the next leg of interest when clarity arrives. This article walks through three stocks from the India–US exposure screener that look especially sensitive to this news flow and shows how investors might think about them now.

The three stocks below are a starting sample. The full screen surfaced 63 more Indian export oriented businesses with U.S. links and equally compelling narratives that sit outside this article.

To identify those extra ideas quickly, go straight to the Indian Export-Oriented Sectors with Significant U.S. Revenue Exposure screener to filter, analyze, and focus on the opportunities that best fit your conviction.

Indegene (NSEI:INDGN)

Overview: Indegene is a Bengaluru based, digital first life sciences commercialization specialist that uses AI enabled services to support global pharma clients.

Operations: Indegene reports ₹9,902 million from Enterprise Medical Solutions, with a further ₹26,896 million in segment adjustments and ₹1,330 million from Others.

Market Cap: ₹143.0b

Indegene plugs directly into the screener theme because it exports high value, tech driven services to large U.S. and European drug makers that are watching policy headlines closely.

"Strong momentum in FY26 and beyond. FY27 guidance: High-teens to 20%+ revenue growth expected on AI/GenAI ramp-up"

How that kind of growth ambition interacts with ongoing pressure on profitability could be important for investors with a long term view.

That tension between ambition and profitability is exactly what the full narrative for Indegene unpacks, showing where Indegene's AI ramp could accelerate or stall the story next.

Samvardhana Motherson International (BSE:517334)

Overview: Samvardhana Motherson International builds wiring harnesses, polymer modules, mirrors and assemblies for global automakers, including U.S. OEMs. This makes it a direct play on export oriented auto supply chains.

Operations: Samvardhana Motherson International generates most revenue from Modules and Polymer Products at ₹645,806 million and Wiring Harness at ₹391,476 million, with Vision Systems and Emerging Businesses contributing ₹215,181 million and ₹181,652 million respectively.

Market Cap: ₹1,658.7b

Samvardhana Motherson International fits the screener theme cleanly, since its components flow into vehicles sold across the U.S. and other major car markets, and recent logistics moves hint at a push to keep that export pipeline resilient if trade rules change.

"Strategic focus on producing and sourcing locally in major markets (for example, U.S., Mexico, China, Europe) insulates operations from disruptive tariffs and geopolitical headwinds, supporting both revenue resilience and sustained profitability.

What happens to margins and order visibility if one key assumption about how global carmakers allocate new content per vehicle shifts.

That kind of shift in assumptions is exactly what the full narrative for Samvardhana Motherson International breaks down, separating short term margin noise from longer term content growth potential.

Viyash Scientific (BSE:512529)

Overview: Viyash Scientific is a Hyderabad based veterinary pharmaceutical group supplying animal health APIs, finished drugs and services to India, the U.S. and other export markets.

Operations: Viyash Scientific reports ₹35,750 million from Pharmaceuticals, reflecting a focused revenue base in veterinary and related formulations.

Market Cap: ₹101.2b

Viyash Scientific plugs into this export oriented pharma theme as a veterinary specialist with clear links to U.S. and European buyers. Any future clarity on India U.S. trade rules could matter more here than for a purely domestic vet drug player.

"Expansion of companion and farm animal formulations across Europe, Latin America, India, Southeast Asia and parts of Africa, supported by EU approved plants in Spain and Turkey and growing field forces in markets like Spain, Benelux, Italy and Brazil, can broaden the volume base and help sustain consolidated revenue growth."

What happens to profitability if one key assumption about how quickly that broader footprint converts into higher margin export sales breaks.

If that export mix is what you care about, the full narrative for Viyash Scientific shows where Viyash Scientific's growth could accelerate, stall or quietly decouple from peers.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. Once a theme catches a bid, prices can start moving quickly and the cleanest entries can disappear. Scan these curated shortlists before the crowd and consider your options early.

• Identify potential early leaders among smaller companies by running through the 118 elite penny stocks with strong financials and finding candidates before any breakout move is fully reflected in prices.
• Explore major technology shifts by scanning the curated 90 AI infrastructure stocks list while many of these enablers may still be less widely followed.
• Focus on steadier cash return profiles with the curated 169 dividend fortresses and reduce the risk of reacting only after payouts have already influenced prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com